Clinical characteristics of CLL patients. Amigo-JiménezIrene BailónElvira Ugarte-BerzalEstefanía Aguilera-MontillaNoemí A. García-MarcoJosé García-PardoAngeles 2014 a<p>Clinical stage according to references <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099993#pone.0099993-Zenz1" target="_blank">[1]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099993#pone.0099993-Gaidano1" target="_blank">[2]</a>.</p>b<p>Percentage of cells expressing this marker.</p>c<p>The coexpression of CD38 and ZAP-70 has clinical prognostic value <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099993#pone.0099993-Zenz1" target="_blank">[1]</a>, <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0099993#pone.0099993-Gaidano1" target="_blank">[2]</a>.</p><p>ND, not determined.</p>